SMARCA4 and cancer: Targeting BRG1,then, should be an effective adjuvant therapy for existing cancer treatments.Other studies linked the chemosensitivity observed upon BRG1 knockdown todeficiencies in DNA repair following exposure to DNA damaging chemotherapeuticdrugs [115–117],suggesting another drug resistance mechanism that would be targeted by methodsreducing BRG1 expression or function.